Butylparaben

Butylparaben

SCHEMBL29376702

CCCCOC(=O)c1ccc(O)cc1.[Na]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 10/20 0.96
TSHR P16473 3/20 0.96
LMNA P02545 2/20 0.96
CYP1A2 P05177 2/20 0.96
CYP2C19 P33261 2/20 0.96
SMN1; SMN2 Q16637 2/20 0.96
CYP2D6 P10635 1/20 0.96
MAPK1 P28482 1/20 0.96
NR1H2 P55055 1/20 0.96
RNASEL Q05823 1/20 0.96
ALDH1A1 P00352 2/20 0.77
CHRM1 P11229 1/20 0.77
SLC6A2 P23975 1/20 0.77
KDR P35968 1/20 0.77
TDP1 Q9NUW8 1/20 0.77
CYP3A4 P08684 1/20 0.70
CYP2C9 P11712 1/20 0.70
PDE4D Q08499 1/20 0.70
CA12 O43570 1/20 0.65
CA1 P00915 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butylparaben SCHEMBL5789201 0.98 ESR1 (1.00) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL3647 0.98 ESR1 (1.00) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL344001 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL27203944 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL761983 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL5152448 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL2325184 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL9172319 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL29377478 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL27875265 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024240033-A1 KETAMINE LIQUID PREPARATION AND USE THEREOF 宜昌人福药业有限责任公司 2024-11-28 WO claimed
CN-118662429-A Ibuprofen eutectic rectal gel and preparation method thereof 南京海融医药科技股份有限公司 2024-09-20 CN claimed
US-20230363380-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2023-11-16 US claimed
EP-3021832-B9 PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2023-03-15 EP claimed
US-20220079145-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2022-03-17 US claimed
EP-4580593-A1 CLEANING PREPARATION FOR PREPARING FOR A SHAVE AND FOR FACE CLEANING Beiersdorf AG (DE) 2025-07-09 EP disclosed
EP-4306168-B1 ISOXAZOLINE COMPOSITIONS AND USE THEREOF IN THE PREVENTION OR TREATMENT OF PARASITE INFESTATIONS IN ANIMALS INTERVET INT BV (NL) 2025-06-25 EP disclosed
EP-4504214-A1 NOVEL ISOXAZOLINE COMPLEXES AND COMPOSITIONS THEREOF Smartek International Inc. (US) 2025-02-12 EP disclosed
WO-2024232970-A1 NOVEL ISOXAZOLINE COMPLEXES AND COMPOSITIONS THEREOF SMARTEK INTERNATIONAL INC (US) 2024-11-14 WO disclosed
US-20240366572-A1 ISOXAZOLINE COMPLEXES AND COMPOSITIONS THEREOF FARBER MICHAEL (US) 2024-11-07 US disclosed
CN-118662429-A Ibuprofen eutectic rectal gel and preparation method thereof 南京海融医药科技股份有限公司 2024-09-20 CN disclosed
EP-4360612-A1 COSMETIC CLEANSING GEL HAVING HIGH TRANSPARENCY Beiersdorf AG (DE) 2024-05-01 EP disclosed
EP-3687497-B1 TOPICAL COMPOSITION AND METHOD FOR TREATING AND PREVENTING ATOPIC DERMATITIS AND INFECTIONS RELATED TO BACTERIA BIOFILM JOHNSON & JOHNSON CONSUMER INC (US) 2023-06-28 EP disclosed
EP-3265135-B1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2023-06-07 EP disclosed
US-11464716-B1 Semi-permanent colorant composition for hair AMERICAN SPRAYTECH, L.L.C. (US) 2022-10-11 US disclosed
EP-3313400-B1 ISOXAZOLINE SOLUTION CONTAINING VITAMIN E FOR USE WITH SANITIZED DRINKING WATER INTERVET INT BV (NL) 2022-06-15 EP disclosed
US-11331305-B2 Peptides for skin rejuvenation and methods of using the same ANTEIS SA (CH) 2022-05-17 US disclosed
US-20220079145-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2022-03-17 US disclosed
CN-114073669-A Gel containing aryl propionic acid compound 南京海融医药科技股份有限公司 2022-02-22 CN disclosed
US-11241385-B2 Topical composition and method for treating and preventing atopic dermatitis and infections related to bacteria biofilm JOHNSON & JOHNSON CONSUMER INC. (US) 2022-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11331305-B2 Peptides for skin rejuvenation and methods of using the same CUTA, PLOD3, MMP13 ESR1 4703/4885TSHR 3828/4885LMNA 408/4885
US-20240366572-A1 ISOXAZOLINE COMPLEXES AND COMPOSITIONS THEREOF CCDC47, CAT, CTTN ESR1 3294/4885TSHR 2889/4885LMNA 3653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.